JW THERAP-B: 2024 ANNUAL REPORT

HKEXApr 28 04:31 ET · Announcements

JW THERAP-B (02126) grants Juno a non-exclusive license for the JW sLVV production process and related technical knowledge.

JW THERAP-B (02126) announced that the company has reached an agreement with one of its major shareholders and related parties, Juno, regarding ...

Zhitong FinanceApr 22 10:52 ET

Express News | JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others

ReutersApr 22 10:44 ET

Positive Sentiment Still Eludes JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Following 34% Share Price Slump

Simply Wall StApr 16 19:26 ET

JW THERAP-B (02126) is issuing 0.4881 million shares according to the stock plan.

JW THERAP-B (02126) issued an announcement that on March 21, 2025, the company will issue based on the share plan...

Zhitong FinanceApr 2 09:22 ET

JW THERAP-B (02126) released its annual performance, with an income of 0.158 billion yuan. It is expected that the sales revenue of Benod will increase again in the next period.

JW THERAP-B (02126) announced its annual performance for the year ending December 31, 2024, with the group achieving revenue...

Zhitong FinanceMar 27 06:35 ET

Express News | JW (Cayman) Therapeutics FY Revenue RMB 158.2 Million

ReutersMar 27 06:25 ET

Express News | JW (Cayman) Therapeutics FY Net Income RMB -590.6 Million

ReutersMar 27 06:25 ET

Express News | JW (Cayman) Therapeutics FY Gross Profit RMB 77.3 Million

ReutersMar 27 06:25 ET

Express News | JW (Cayman) Therapeutics FY Gross Margin 48.9%

ReutersMar 27 06:25 ET

JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 27 06:24 ET · Announcements

JW THERAP-B (02126) entered into a material transfer agreement with Juno.

JW THERAP-B (02126) announces that on March 19, 2025, the company will collaborate with Juno (the main company...)

Zhitong FinanceMar 19 05:06 ET

JW THERAP-B (02126.HK) plans to hold a Board of Directors meeting on March 27 to approve the annual performance.

Gelonghui announced on March 17 that JW THERAP-B (02126.HK) has scheduled a Board of Directors meeting on March 27, 2025 (Thursday), to (including) (i) consider and approve the group's audited consolidated results for the year ending December 31, 2024, and its publication; (ii) propose a final dividend (if any); and (iii) address any Other matters.

Gelonghui FinanceMar 17 06:05 ET

JW THERAP-B: NOTICE OF BOARD MEETING

HKEXMar 17 06:04 ET · Announcements

JW THERAP-B (02126.HK): Liu Min has been appointed as the chairman of the Board of Directors.

Gelonghui, March 14丨JW THERAP-B (02126.HK) announced that after Li Yiping's resignation as chairman, the current CEO and executive director Liu Min has been appointed as the chairman of the Board of Directors, effective from March 13, 2025.

Gelonghui FinanceMar 14 10:34 ET

Express News | JW (Cayman) Therapeutics - Min Liu Appointed as Chairman of Board

ReutersMar 14 10:28 ET

Hong Kong Stock Market Review | Hang Seng Index dropped 1.38% in the morning, while most CRO Concept stocks rose.

Most Concept stocks related to CRO have risen, and the Industry is expected to enter a stable growth phase. AI pharmaceutical technology and others are worth paying attention to.

Zhitong FinanceFeb 19 23:00 ET

JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Shares Leap 32% Yet They're Still Not Telling The Full Story

Simply Wall StFeb 14 18:32 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

Express News | JW (Cayman) Therapeutics - Nmpa China Granted Breakthrough Therapy Designation for Carteyva (Relmacabtagene Autoleucel Injection)

ReutersJan 10 03:31 ET